PLAU and pancreatic neoplasm: In addition, the small molecule uPA inhibitor, WX-671, was tested in a phase II trial in patients with locally advanced non-metastatic pancreatic cancer; however, in the study, the combination of WX-671 and gemcitabine, a nucleoside analog used as a chemotherapeutic agent, was shown to be well tolerated, but the survival outcomes of the combination group were similar to those in the gemcitabine-only group [137].